£400M Investment to Establish Clinical Trial Hubs Across the UK
Key Insights
A £400 million public-private investment will establish up to 18 new clinical trial hubs across the UK to accelerate the development of new medicines.
The investment aims to enhance the UK's clinical trials infrastructure, improve patient recruitment, and provide researchers with access to advanced technology.
The initiative is a collaboration between the Department of Health and Social Care, NHS England, and the Association of the British Pharmaceutical Industry (search).
A substantial £400 million investment, combining public and private funds, will facilitate the creation of up to 18 new clinical trial hubs throughout the United Kingdom. This initiative aims to expedite the development and delivery of innovative medicines to patients. The investment is expected to significantly enhance the UK's standing as a global leader in health research and improve patient access to cutting-edge treatments.
The Voluntary Scheme for Branded Medicine Pricing, Access, and Growth (VPAG) Investment Programme is a collaborative effort between the Department of Health and Social Care (DHSC), NHS England, and the Association of the British Pharmaceutical Industry (search) (ABPI). This program is designed to bolster health and life sciences projects across the UK.
Expanding Clinical Trial Capacity
Approximately 75% of the £400 million investment will be dedicated to expanding the UK’s capacity for commercial clinical trials. This will involve establishing up to 18 new Commercial Research Delivery Centres (CRDCs) across the four nations. These hubs will strengthen the UK’s trials infrastructure and support the recruitment of patients into clinical trials. Researchers will also gain access to state-of-the-art equipment and technology, enabling trials to be conducted in various settings, including hospitals and residential care facilities.
According to Health Secretary Wes Streeting, this private investment represents “a significant vote of confidence in the UK” and will transform the country into “the epicenter of health research, supporting an NHS fit for the future.”
Sustainable Manufacturing and Innovative Assessment
Around 20% of the funding will support sustainable manufacturing initiatives within the pharmaceutical sector, promoting efficiency and reducing waste and emissions. The remaining funds will be used to modernize the assessment of the cost and clinical effectiveness of new treatments. This includes support for the National Institute for Health and Care Excellence (NICE) and the HTA (Health Technology Assessment) Innovation Laboratory, as well as the creation of a new database called UK Pharmascan, which will provide information on new medicines entering the market.
Industry Perspective
Richard Torbett, chief executive of the ABPI, emphasized the potential of the life science industry to contribute to the UK's growth, stating, “This world-first investment program puts industry money behind the Government’s vision to make better health and science a driver of economic growth.”
Broader Impact
The investment program aligns with the government’s broader goals of stimulating economic growth and improving patient care. By enhancing the UK’s clinical trials capabilities, the initiative aims to attract further global investment and solidify the country’s position as a leader in life sciences.